Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

INTRODUCTION: The selective estrogen receptor degrader fulvestrant is approved for the first-line treatment of postmenopausal patients with hormone receptor-positive (HR+), locally advanced or metastatic breast cancer who have not received prior endocrine therapy. We evaluated the cost-effectiveness...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacoecon Open
Hlavní autoři: Telford, Claire, Bertranou, Evelina, Large, Samuel, Phelps, Hilary, Ekman, Mattias, Livings, Christopher
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2019
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6861400/
https://ncbi.nlm.nih.gov/pubmed/31025302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-0134-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky